(0.61%) 5 077.25 points
(0.37%) 38 211 points
(0.83%) 17 582 points
(0.72%) $79.57
(2.23%) $1.975
(0.17%) $2 315.00
(-0.27%) $26.68
(0.93%) $963.80
(0.10%) $0.934
(0.31%) $11.06
(0.02%) $0.799
(-1.41%) $91.95
Live Chart Being Loaded With Signals
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers...
Stats | |
---|---|
今日成交量 | 313 195 |
平均成交量 | 684 778 |
市值 | 4.17M |
EPS | $-0.105 ( 2023-11-13 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.339 |
ATR14 | $0.0350 (19.34%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-15 | Milby Randy | Buy | 29 000 | Common Stock |
2023-11-30 | Milby Randy | Buy | 10 000 | Common Stock |
2023-11-07 | Bui Lynne A. | Buy | 25 000 | Options (right to buy) |
2023-11-07 | Appajosyula Sireesh | Buy | 25 000 | Options (right to buy) |
2023-11-07 | Anderson Kelly | Buy | 50 000 | Options (right to buy) |
INSIDER POWER |
---|
95.97 |
Last 99 transactions |
Buy: 3 498 545 | Sell: 667 792 |
音量 相关性
Hillstream BioPharma, 相关性 - 货币/商品
Hillstream BioPharma, 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-7.14 |
FY | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-7.14 |
FY | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-0.750 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.196 |
Financial Reports:
No articles found.
Hillstream BioPharma,
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。